Keller CW, Ruck T, Mchugh D, Pfeuffer S, Gross CC, Korsukewitz C, Melzer N, Klotz L, Meuth SG, Muenz C, Nimmerjahn F, Wiendl H, Luenemann JD (2019)
Publication Type: Journal article
Publication year: 2019
DOI: 10.1002/acn3.50935
Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell-depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing-remitting multiple sclerosis. No differences in clinical and MRI-based efficacy parameters, the development of severe infusion-associated reactions and secondary autoimmune diseases during a 2 year follow-up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.
APA:
Keller, C.W., Ruck, T., Mchugh, D., Pfeuffer, S., Gross, C.C., Korsukewitz, C.,... Luenemann, J.D. (2019). Impact of Fc gamma R variants on the response to alemtuzumab in multiple sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.50935
MLA:
Keller, Christian W., et al. "Impact of Fc gamma R variants on the response to alemtuzumab in multiple sclerosis." Annals of Clinical and Translational Neurology (2019).
BibTeX: Download